Loading organizations...
Compass Therapeutics is a technology company.
Compass Therapeutics has raised $49.0M across 1 funding round.
Compass Therapeutics has raised $49.0M in total across 1 funding round.
We are developing next generation antibodies into transformative cancer therapies that improve patients’ lives. We leverage our understanding of the tumor microenvironment to develop product candidates designed to optimize anti-tumor responses.
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology and autoimmune diseases.[1][2] The company targets the tumor microenvironment by modulating angiogenesis, enhancing immune responses, and countering tumor immunosuppression through monoclonal and multispecific antibodies like StitchMabs™, serving cancer patients and those with autoimmune conditions.[1][2][3] Its pipeline addresses over 40 immune targets, with candidates advancing in clinical trials as standalone or combination therapies, demonstrating growth through ongoing development and recent conference participation.[2][3]
Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics emerged with a focus on the interplay between angiogenesis, the immune system, and tumor growth.[1] The company's unbiased drug discovery approach leverages proprietary platforms like StitchMabs™ and common light chain technology to rapidly generate diverse antibody candidates.[2] Early traction built on nonclinical data supporting pipeline advancement, evolving into a robust portfolio bridging innate and adaptive immunity, led by a leadership team experienced in drug discovery and development.[1][2]
Compass rides the immuno-oncology wave, targeting the immune synapse with next-generation antibodies amid rising demand for combination therapies in solid tumors and autoimmune disorders.[2][3] Timing aligns with advances in bispecific antibodies and tumor microenvironment understanding, fueled by market forces like clinical trial momentum and investor interest in precision biologics.[1][3] By influencing antibody engineering standards, Compass contributes to the biopharma ecosystem, enabling transformative therapies that optimize innate-adaptive immunity bridges.[2]
Compass is poised to expand its clinical pipeline, with upcoming milestones like the J.P. Morgan 2026 Healthcare Conference signaling partnership and trial advancements.[3] Trends in multispecific antibodies and immune synapse modulation will shape its trajectory, potentially amplifying influence through combo regimens and autoimmune expansions.[2] As a Boston-based innovator, its empirical discovery engine positions it to deliver patient-impacting therapies, building on oncology roots to redefine immune-targeted biopharma.
Compass Therapeutics has raised $49.0M in total across 1 funding round.
Compass Therapeutics's investors include Carl Gordon, Atlas Venture, F-Prime Capital Partners, Alexandria Venture Investments, Biomatics Capital, BioMed Ventures, Borealis Ventures, Cowen Healthcare Investments, F-Prime Capital, Thiel Capital, Ulysses Diversified Holdings.
Compass Therapeutics has raised $49.0M across 1 funding round. Most recently, it raised $49.0M Series A in July 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2018 | $49.0M Series A | Carl Gordon | Atlas Venture, F-Prime Capital Partners, Alexandria Venture Investments, Biomatics Capital, BioMed Ventures, Borealis Ventures, Cowen Healthcare Investments, F-Prime Capital, Thiel Capital, Ulysses Diversified Holdings |